Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jul 2024 The timeframe for the primary endpoint changed from "From the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 16 weeks" to "From the date of informed consent to radiographically documented progression according to RECIST 1.1, assessed up to 16 week
08 May 2024 Planned End Date changed from 30 Nov 2023 to 31 Dec 2024.
08 May 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com